Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors

被引：0
|
作者：
Pilotto, Sara [1 ]
Bria, Emilio [1 ]
机构：
[1] Univ Verona, Azienda Osped Univ Integrata, GB Rossi Acad Hosp, Med Oncol, Verona, Italy
来源：
LUNG CANCER MANAGEMENT | 2013年 / 2卷 / 02期
关键词：
D O I：
10.2217/LMT.12.57
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：89 / 92
页数：4
相关论文
共 50 条
  • [31] Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
    Yonesaka, Kimio
    Iwama, Eiji
    Hayashi, Hidetoshi
    Suzuki, Shinichiro
    Kato, Ryoji
    Watanabe, Satomi
    Takahama, Takayuki
    Tanizaki, Junko
    Tanaka, Kaoru
    Takeda, Masayuki
    Sakai, Kazuko
    Azuma, Koichi
    Chiba, Yasutaka
    Atagi, Shinji
    Nishio, Kazuto
    Okamoto, Isamu
    Nakagawa, Kazuhiko
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [32] Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
    Kimio Yonesaka
    Eiji Iwama
    Hidetoshi Hayashi
    Shinichiro Suzuki
    Ryoji Kato
    Satomi Watanabe
    Takayuki Takahama
    Junko Tanizaki
    Kaoru Tanaka
    Masayuki Takeda
    Kazuko Sakai
    Koichi Azuma
    Yasutaka Chiba
    Shinji Atagi
    Kazuto Nishio
    Isamu Okamoto
    Kazuhiko Nakagawa
    Scientific Reports, 9
  • [33] Tyrosine kinase inhibitors alone as a first-line treatment for patients with non-small-cell lung cancer harboring mutant epidermal growth factor receptor
    Iuchi, T.
    Shingyoji, M.
    Itakura, M.
    Hasegawa, Y.
    Yoshida, Y.
    Ikegami, S.
    Setoguchi, T.
    Ashinuma, H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated With First-Line EGFR Tyrosine Kinase Inhibitors
    Jiang, Tao
    Zhao, Jing
    Zhao, Chao
    Li, Xuefei
    Shen, Jiqiao
    Zhou, Juan
    Ren, Shengxiang
    Su, Chunxia
    Zhou, Caicun
    O'Brien, Mary
    CLINICAL LUNG CANCER, 2019, 20 (02) : 124 - +
  • [35] The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation
    Sgambato, A.
    Casaluce, F.
    Maione, P.
    Rossi, A.
    Rossi, E.
    Napolitano, A.
    Palazzolo, G.
    Bareschino, M. A.
    Schettino, C.
    Sacco, P. C.
    Ciadiello, F.
    Gridelli, C.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (20) : 3337 - 3352
  • [36] Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
    Zucali, P. A.
    Ruiz, M. G.
    Giovannetti, E.
    Destro, A.
    Varella-Garcia, M.
    Floor, K.
    Ceresoli, G. L.
    Rodriguez, J. A.
    Garassino, I.
    Comoglio, P.
    Roncalli, M.
    Santoro, A.
    Giaccone, G.
    ANNALS OF ONCOLOGY, 2008, 19 (09) : 1605 - 1612
  • [37] Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
    Gomes, Jessica Ribeiro
    Cruz, Marcelo Rocha S.
    ONCOTARGETS AND THERAPY, 2015, 8 : 1137 - 1142
  • [38] Consolidative Stereotactic Radiotherapy in Metastatic EGFR-Mutant Non-Small Cell Lung Cancer Receiving First-Line Third-Generation EGFR Tyrosine Kinase Inhibitors: A Prospective Phase II Trial
    Zhou, Y.
    Ni, J.
    Zhu, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S94 - S94
  • [39] EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC)
    Nassar, Amin
    Adib, Elio
    Feng, Jamie
    Aredo, Jacqueline V.
    Parikh, Kaushal
    Harris, Jeremy Phillip
    Manana, Ana I. Velazquez
    Ragavan, Meera Vimala
    Lin, Jessica Jiyeong
    Piotrowska, Zofia
    Fitzgerald, Bailey Gleason
    Grohe, Christian
    Sankar, Kamya
    Neal, Joel W.
    Wakelee, Heather A.
    Shepherd, Frances A.
    Herbst, Roy S.
    Naqash, Abdul Rafeh
    Goldberg, Sarah B.
    Kim, So Yeon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p).
    Garcia Campelo, Rosario
    Moran, Teresa
    Cardenal, Felipe
    Alonso-Jaudenes Curbera, Guillermo
    Carcereny Costa, Enric
    Pallares, Cinta
    Camps, Carlos
    Insa, Amelia
    Lopez-Vivanco, Guillermo
    Porta, Rut
    Bastus, Roma
    Isla, Dolores
    Reguart, Noemi
    Bover, Isabel
    Majem, Margarita
    Massuti, Bartomeu
    Luis Ramirez, Jose
    Drozdowskyj, Ana
    Karachaliou, Niki
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345